Nonetheless, a separate Examination from Delveinsight suggests that although Epidyolex is about to continue dominating the sector and staying a essential earner for Jazz from the in close proximity to foreseeable future, a increasing quantity of viable alternate solutions while in the rare epilepsies, particularly from bexicaserin and zorevunersen,